Watch Shares of BIEL closely Print E-mail
By Staff and Wire Reports   
Monday, 28 September 2009 16:49
Make a note to keep an eye on shares of BioElectronics (OTC:BIEL) starting tomorrow morning, as the company has been working with the Pinksheets to remove the 'Caveat Emptor' notice which has prevented the stock from trading to it's maximum potential the last few weeks.

As we understand it, the company has submitted sustantial amounts of paperwork in order to get the trading exchange to  have their status changed to "Fully Reporting" and they expect that the change may happen at any moment.

Shares would be expected to rise upon that development as they would upon any news regarding the company's application to the FDA. An approval decision from the agency is also expected any day.

BioElectronics Corporation (BioElectronics) designs, develops and markets a variety of drug-free, anti-inflammatory patches for a range of medical indications. The Company's patch products, which are marketed under the name ActiPatch Therapy, deliver pulsed electromagnetic field therapy, an anti-inflammatory and pain relief therapy.

The ActiPatch Therapy products combine a miniaturized microchip, power source and antenna in a soft, flexible outer envelope. When applied to the body, these devices deliver a pulsed radio frequency signal into the body on a 27 megahertz (MHz) frequency wave that induces a low frequency electromagnetic field to damaged cell tissue.

Click on this link for all our past coverage about this momentum driven small cap stock.

UPDATE: At mid day on tuesday, the company announced its trading status update as The Pink Sheets Current Information Tier, under the ticker symbol BIEL. BioElectronics is continuing to provide full transparency to investors and broker-dealers following the guidelines provided by Pink OTC Markets, Inc.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter